Suppression of Development of Ankylosing Spondylitis Through Soluble Flt-1

Area of Science:

• Immunology
• Rheumatology
• Molecular Biology

Background:

• Ankylosing spondylitis (AS) pathogenesis involves osteoclast precursors from circulating monocytes/macrophages.
• Infiltrated macrophages exacerbate AS by secreting pro-inflammatory cytokines.
• Targeting monocyte/macrophage recruitment offers a potential therapeutic strategy for AS.

Purpose of the Study:

• To investigate the therapeutic potential of soluble fms-like tyrosine kinase-1 (sFlt-1) in a mouse model of ankylosing spondylitis (AS).
• To evaluate the effect of sFlt-1 on the recruitment of circulating monocytes/macrophages in AS.
• To explore the mechanism of sFlt-1 action, particularly its interaction with vascular endothelial growth factor (VEGF) signaling.

Main Methods:

• Utilized a proteoglycan-induced arthritis (PGIA) mouse model to simulate human AS.
• Administered sFlt-1 intra-articularly and assessed its impact on arthritis incidence and severity.
• Analyzed macrophage and endothelial cell populations within the articular cavity post-treatment.

Main Results:

• Intra-articular sFlt-1 injection significantly reduced PGIA incidence and severity in mice.
• sFlt-1 treatment led to a significant decrease in infiltrated macrophages within the joint.
• The observed reduction in macrophages was potentially mediated by decreased vessel permeability in a VEGFR2-dependent manner.

Conclusions:

• sFlt-1 demonstrates therapeutic potential for ankylosing spondylitis.
• sFlt-1 may exert its therapeutic effects by suppressing VEGF signaling, thereby inhibiting monocyte/macrophage recruitment.
• This study highlights sFlt-1 as a promising candidate for AS treatment by targeting key inflammatory pathways.